These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11311353)

  • 1. Simple detection of point mutations associated with HIV-1 drug resistance.
    Frater AJ; Chaput CC; Beddows S; Weber JN; McClure MO
    J Virol Methods; 2001 Apr; 93(1-2):145-56. PubMed ID: 11311353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
    Clarke JR; Kaye S; Babiker AG; Hooker MH; Tedder R; Weber JN
    J Virol Methods; 2000 Aug; 88(2):117-24. PubMed ID: 10960699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
    Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.
    Saeng-Aroon S; Yoshida LM; Ariyoshi K; Taguchi M; Pathipvanich P; Rojanawiwat A; Matsuda M; Kannagi M; Sawanpanyalert P; Sugiura W; Auwanit W
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1461-8. PubMed ID: 18160002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
    Schmit JC; Ruiz L; Stuyver L; Van Laethem K; Vanderlinden I; Puig T; Rossau R; Desmyter J; De Clercq E; Clotet B; Vandamme AM
    J Virol Methods; 1998 Jul; 73(1):77-82. PubMed ID: 9705178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients.
    Birk M; Sönnerborg A
    AIDS; 1998 Dec; 12(18):2369-75. PubMed ID: 9875574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.
    Beck IA; Crowell C; Kittoe R; Bredell H; Machaba M; Willamson C; Janssens W; Jallow S; van der Groen G; Shao Y; Jacob M; Samuel NM; de Rivera IL; Ngo-Giang-Huong N; Cassol S; Alemnji G; Frenkel LM
    J Acquir Immune Defic Syndr; 2008 Aug; 48(4):418-27. PubMed ID: 18614915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid detection of the HIV type 1 reverse transcriptase codon T215Y by reverse transcription-polymerase chain reaction with fluorogenic probes.
    Ross L; Vavro C; Zimmermann A; St Clair M
    AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1287-92. PubMed ID: 10505677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.
    Aitken SC; Kliphuis A; Wallis CL; Chu ML; Fillekes Q; Barth R; Stevens W; Rinke de Wit TF; Schuurman R
    J Clin Virol; 2012 May; 54(1):21-5. PubMed ID: 22306272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.
    Chen JH; Wong KH; Chan K; Lam HY; Lee SS; Li P; Lee MP; Tsang DN; Zheng BJ; Yuen KY; Yam WC
    J Clin Virol; 2007 Jun; 39(2):125-31. PubMed ID: 17449318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals.
    Shafer RW; Warford A; Winters MA; Gonzales MJ
    J Virol Methods; 2000 May; 86(2):143-53. PubMed ID: 10785289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
    Cunningham PH; Smith DG; Satchell C; Cooper DA; Brew B
    AIDS; 2000 Sep; 14(13):1949-54. PubMed ID: 10997399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral resistance during successful therapy of HIV type 1 infection.
    Martinez-Picado J; DePasquale MP; Kartsonis N; Hanna GJ; Wong J; Finzi D; Rosenberg E; Gunthard HF; Sutton L; Savara A; Petropoulos CJ; Hellmann N; Walker BD; Richman DD; Siliciano R; D'Aquila RT
    Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10948-53. PubMed ID: 11005867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
    Newman H; Breunig L; van Zyl G; Stich A; Preiser W
    J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.